Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on October 16, 2025
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and optionality TSHA-102 has demonstrated …
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Theriva™ Biologics anuncia una operación de incentivo de warrants por un importe bruto de 4 millones de dólares
ROCKVILLE, Maryland, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), («Theriva» o la «empresa»), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en …
Le R&D Day de Cellectis souligne le potentiel de lasmé-cel pour combler un besoin médical majeur non satisfait chez les patients atteints de LAL-B en rechute ou réfractaire
○ Efficacité : taux de réponse global (ORR) de 68 % avec le Process 2 de lasmé-cel (P2) (n=22) ; 83 % à la dose recommandée de Phase 2 (RP2D, n=12) ; et 100 % dans la population cible de Phase 2 (n=9)1 ○ Sécurité : en Phase 1 (n=40), lasmé-cel a été …
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability …
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
PRESS RELEASE AB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA Paris, 16 October 2025, 9pm CET AB Science SA (Euronext - FR0010557264 - AB) today …
AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute
COMMUNIQUÉ DE PRESSE AB SCIENCE PRESENTE LES PREMIÈRES DONNÉES DE PHASE 1 DE LA COMBINAISON D’AB8939 ET DU VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN RECHUTE Paris, le 16 octobre 2025, 21h00 AB Science SA (Euronext - …
Wounded Warriors Family Support Donates 2025 Ford F-150 Truck to Retired Marines Veteran
KING OF PRUSSIA, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- A deserving veteran received the life-changing gift of mobility after a considerable donation Tuesday at Topgolf King of Prussia. Wounded Warriors Family Support and Radian Group Inc. donated a 2025 …
Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030
Boston, Oct. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Anti-Parkinson's Drugs: Global Markets to 2030” is projected to grow from $6.1 billion in 2025 to $9.2 billion by the end of 2030, at a compound annual growth rate …
Celebrating 50 Years of Katena: From One Woman’s Vision to a Global Legacy in Ophthalmology
PARSIPPANY, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a global medical technology company, is proud to celebrate the 50-year anniversary of Katena, a brand that has defined excellence in ophthalmology since its founding in 1975 by Kate …
Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
New York, USA, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight Thyroid Eye Disease (TED), also known as Graves’ ophthalmopathy, is a …
聽證會取消後，Apollomics 宣佈繼續於 The Nasdaq Stock Market 維持其上市地位
加州福斯特城, Oct. 17, 2025 (GLOBE NEWSWIRE) -- 總部設於加州的 Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「公司」) 是一家晚期臨床生物製藥公司，開發多種腫瘤候選藥物對抗難以根治及對治療有抗藥性的癌症。該公司較早時宣佈已向 The Nasdaq Stock Market, LLC (簡稱「Nasdaq」) 之上市資格人員（簡稱「上市資格人員」）提交申請，對先前收到之除牌通知提出上訴，並要求在 Nasdaq …
Press release: NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
Ghent, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 16 October 2025 – Sequana Medical NV (Euronext …
Profesor estadounidense recibe tratamiento cardíaco en Xiamen
XIAMEN, China, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Kevin Klein, un profesor estadounidense de la Escuela Internacional de Xiamen, se sometió a una angiografía coronaria y una ablación por radiofrecuencia el 26 de septiembre en el Hospital Cardiovascular de …
Channel Medsystems Strengthens Commercial Leadership Team with Appointments of Tara Murphy as Vice President of Marketing and Paul Russo as Vice President of Sales
BERKELEY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointments of Tara Murphy as Vice President of Marketing and Paul …
CAOT Announces On the Move: The Canadian Driving Rehabilitation and Transportation Conference
Ottawa, ON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Canadian Association of Occupational Therapists (CAOT) is pleased to announce that On the Move: The Canadian Driving Rehabilitation and Transportation Conference will take place November 18-19, 2025, at the …
Global Portable Ultrasound Market Set to Reach USD 3.84 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The global portable ultrasound market, valued at US$2.16 billion in 2023, stood at US$2.49 billion in 2025 and is projected to advance at a resilient CAGR of 9.0% from 2025 to 2030, culminating in a …
TalkingParents Recognizes National Domestic Violence Awareness Month, Offers Support for Safer Co-Parent Communication
FORT WALTON BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- In recognition of National Domestic Violence Awareness Month, TalkingParents, a trusted leader in co-parenting and family communication, is focusing attention on the profound impact of domestic …